Table 3.
Safety overview in patients with erythrodermic psoriasis or generalized pustular psoriasis
| Adverse event,a n (%) | Erythrodermic psoriasis (N = 8) | Generalized pustular psoriasis (N = 5) | ||
|---|---|---|---|---|
| 0–52 weeksb | After 52 weeksc | 0–52 weeksb | After 52 weeksc | |
| Patients with ≥ 1 TEAE | 7 (87.5) | 8 (100) | 5 (100) | 5 (100) |
| Mild | 3 (37.5) | 4 (50.0) | 2 (40.0) | 3 (60.0) |
| Moderate | 3 (37.5) | 4 (50.0) | 3 (60.0) | 2 (40.0) |
| Severe | 1 (12.5) | 0 | 0 | 0 |
| AE leading to discontinuation | 0 | 2 (25.0) | 0 | 0 |
| Deaths | 0 | 0 | 0 | 0 |
| SAEs | 0 | 0 | 0 | 0 |
a
Adverse events were included regardless of their relationship with the study drug.
b
Note: these data, except for the severity data, have been published previously.9
c
After 52‐week data do not include AEs that occurred between 0 and 52 weeks.
AE, adverse event; SAEs, serious adverse events; TEAE, treatment‐emergent dverse event.